Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Monday, May 5, 2014. Pfizer Inc. (NYSE:PFE) stock performance was 1.05% in last session and finished the day at $31.82. Traded volume was 21.09million shares in the last session and the average volume of the stock remained 26.39million shares. The beta of the stock remained 0.66. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

In a time when medical costs seem to be soaring in the U.S., we have yet another drug that has been priced superficially at $1000 a pill or roughly $84,000 for a 12 week course and is under scrutiny. The drug in question here is Sovaldi, which is being touted to tackle hepatitis C, a chronic disease that is widespread and affects over 3 million people in the entire country. Writing a letter to Gilead Sciences, Inc. (NASDAQ:GILD)’s Chief Executive John C. Martin, two Democratic lawmakers have asked to explain the reason, behind the exorbitant pricing of the drug. Gilead Sciences Inc. (NASDAQ:GILD) rose 1.25 percent to $73.09 Tuesday on volume of 19.14million shares. The intra-day range of the stock was $71.90 to $74.30.Gilead Sciences Inc. (NASDAQ:GILD) has a market capitalization of $112.02billion.

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86% of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician’s Global Assessment (PGA) score of cleared or minimal at week 16, the study’s primary endpoint, US health care giant Johnson & Johnson (NYSE:JNJ) Janssen unit has said. Johnson & Johnson (NYSE:JNJ)’s stock on Mar 25, 2014 reported a increase of 2.29% to the closing price of $97.38. Its fifty two weeks range is $77.19 -$95.93. The total market capitalization recorded $274.61billion. The overall volume in the last trading session was 14.15million shares. In its share capital, JNJ has 2.82million outstanding shares.

Merck & Co. Inc (NYSE: MRK) continues to bounce around. After shares slipped more than 1% yesterday, they have popped back up 2.70% to $55.23 in a 52-week range of $43.77 to $57.65. There is a report that Sanofi (NYSE: SFY) may join the line of potential buyers for Merck’s consumer health business. On Tuesday, shares of Merck & Co. Inc. (NYSE:MRK) advanced 2.62% to close the day at $55.19. Company return on investment (ROI) is 6.60% and its monthly performance is recorded as -0.99%. Merck & Co. Inc. (NYSE:MRK) quarterly revenue growth is 12.77%.